Oncology

Black Diamond Therapeutics Presents Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium

Monday, October 26, 2020 - 11:45am

and NEW YORK, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the presentation of pre-clinical data on the Companys lead product candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium on Molecular Targets and Cancer Therapeutics (ENA 2020).

Key Points: 
  • and NEW YORK, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the presentation of pre-clinical data on the Companys lead product candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium on Molecular Targets and Cancer Therapeutics (ENA 2020).
  • The presentation from the ENA 2020 meeting is available on the Scientific Presentations and Publications section of the Black Diamond Therapeutics website.
  • Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies.
  • Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry.

Spectrum Pharmaceuticals Announces that the FDA is Deferring its Action on the BLA for ROLONTIS® (eflapegrastim)

Monday, October 26, 2020 - 11:00am

Therefore, the FDA is deferring action on the application until an inspection can be completed.

Key Points: 
  • Therefore, the FDA is deferring action on the application until an inspection can be completed.
  • We are actively working with the FDA to find a way to expedite the plant inspection, said Joe Turgeon, President and CEO, Spectrum Pharmaceuticals.
  • SPECTRUM PHARMACEUTICALS, INC. and ROLONTIS are registered trademarks of Spectrum Pharmaceuticals, Inc. and its affiliate.
  • REDEFINING CANCER CARE and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

Forma Therapeutics Announces Positive Top-line Olutasidenib Data From a Planned Interim Analysis of a Registrational Phase 2 Clinical Trial in Acute Myeloid Leukemia (AML)

Monday, October 26, 2020 - 11:05am

We are pleased to announce these compelling top-line data, said Patrick Kelly, MD, chief medical officer of Forma Therapeutics.

Key Points: 
  • We are pleased to announce these compelling top-line data, said Patrick Kelly, MD, chief medical officer of Forma Therapeutics.
  • Phase 1 of the trial, FT2102-HEM-101, was an open-label, dose-escalation and expansion study of olutasidenib alone and in combination with azacitidine (AZA).
  • The pivotal Phase 2 study is an open-label, fixed-dose study of olutasidenib as a monotherapy in IDH1m AML patients.
  • Forma is currently evaluating olutasidenib in a registrational Phase 2 trial for relapsed/refractory AML and in an exploratory Phase 1 trial for glioma and other solid tumors.

Sage Science to Distribute Universal Sequencing Technology’s TELL-Seq™ Linked-Read NGS Library Prep Kits

Monday, October 26, 2020 - 11:30am

Sage Science, a developer of products for improving sample preparation processes in life science applications, and Universal Sequencing Technology today announced a distribution agreement to improve scientists access to long-range genomic information produced from short-read sequencing platforms.

Key Points: 
  • Sage Science, a developer of products for improving sample preparation processes in life science applications, and Universal Sequencing Technology today announced a distribution agreement to improve scientists access to long-range genomic information produced from short-read sequencing platforms.
  • Through the agreement, Sage Science will distribute Universal Sequencing Technologys TELL-Seq kits to biologists in the U.S., including to users of its HLS-CATCH technique for targeting and analyzing large genomic elements.
  • The process yields intact genomic regions that are up to 500 kilobases in length, preserving them for analysis with targeted sequencing.
  • TELL-Seq kits can be used to barcode molecules for linked-read analysis that makes it possible to characterize long-range information from short-read sequencing platforms.

Acceleron to Webcast Third Quarter 2020 Operating and Financial Results on November 5, 2020

Monday, October 26, 2020 - 11:00am

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, November 5, 2020 at 5:00 p.m. EST to discuss its third quarter 2020 operating and financial results.

Key Points: 
  • Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, November 5, 2020 at 5:00 p.m. EST to discuss its third quarter 2020 operating and financial results.
  • The archived webcast will be available for replay on the Acceleron website approximately two hours after the event.
  • Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.
  • In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having recently presented positive topline results of the PULSAR Phase 2 trial.

Castle Biosciences to Release Third Quarter 2020 Financial Results and Host Conference Call on Monday, November 9, 2020

Monday, October 26, 2020 - 11:00am

Company management will host a conference call and webcast to discuss its financial results and provide a corporate update at 4:30 p.m. Eastern time on the same day.

Key Points: 
  • Company management will host a conference call and webcast to discuss its financial results and provide a corporate update at 4:30 p.m. Eastern time on the same day.
  • A live webcast of the conference call can be accessed at https://edge.media-server.com/mmc/p/77jh5cib or via the webcast link on the Investor Relations page of the Companys website ( www.castlebiosciences.com ).
  • Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq and are trademarks of Castle Biosciences, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005007/en/

Scorpion Therapeutics Launches with $108 Million to Advance Precision Oncology 2.0

Monday, October 26, 2020 - 10:00am

Our deep capabilities in next-generation chemistry enable us to design precision therapeutics for both new targets and those previously dismissed as undruggable.

Key Points: 
  • Our deep capabilities in next-generation chemistry enable us to design precision therapeutics for both new targets and those previously dismissed as undruggable.
  • Scorpion has assembled the talent and technology to address these current limitations and developed a strategy to deliver on the full promise of precision oncology.
  • Scorpion Therapeutics was founded to broaden the reach and impact of precision medicine to more people with cancer.
  • The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0.

Boundless Bio Presents Research Showcasing its Imaging and Single-Cell Sequencing Platform for Extrachromosomal DNA (ecDNA) Detection at the 2020 American Society of Human Genetics (ASHG) Virtual Annual Meeting

Monday, October 26, 2020 - 10:00am

Boundless Bio , a biotechnology company developing innovative therapeutics directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today will present research highlighting powerful components of its proprietary Spyglass platform at the 2020 American Society of Human Genetics (ASHG) Annual Meeting.

Key Points: 
  • Boundless Bio , a biotechnology company developing innovative therapeutics directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today will present research highlighting powerful components of its proprietary Spyglass platform at the 2020 American Society of Human Genetics (ASHG) Annual Meeting.
  • The poster, titled A Robust Imaging and Single-Cell Sequencing Platform to Characterize Tumor Extrachromosomal DNA (ecDNA) in Response to Therapeutic Intervention , describes elements of Boundless Bios broad platform for interrogating ecDNA biology.
  • Tumors driven by oncogene amplification are aggressive, have poor prognosis, and have proven elusive for targeted therapies.
  • Extrachromosomal DNA, or ecDNA, are distinct circular units of DNA containing functional genes, including oncogenes, that are separated from tumor cell chromosomes.

NANOBIOTIX Provides Updates on Global Clinical Development Plan for First-in-class Radioenhancer NBTXR3 at ASTRO 2020

Monday, October 26, 2020 - 7:00am
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20201026005205/en/
    NANOBIOTIX (Euronext : NANO ISIN : FR0011341205 the Company) today announced updates to the Companys global development plan for first-in-class radioenhancer NBTXR3 at the 2020 American Society for Radiation Oncology (ASTRO) Annual Meeting.
  • Nanobiotix has presented an update on the expansion part of the Companys phase I study evaluating NBTXR3 activated by radiation therapy for patients with head and neck cancer (Study 102) at ASTRO 2020.
  • This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development.
  • The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix.

Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral CDK7 Inhibitor, at EORTC-NCI-AACR Meeting

Saturday, October 24, 2020 - 12:30pm

SY-5609 is a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor.

Key Points: 
  • SY-5609 is a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor.
  • As we move forward in this trial, we are committed to fully exploring the potential of SY-5609.
  • The data showed that:
    SY-5609 demonstrated dose-dependent increases in POLR2A mRNA expression, a PD marker being used in the trial to measure CDK7 biological activity.
  • Syros expects to report additional dose-escalation data, including clinical activity data, in mid-2021.